Helmut
★★★
avatar
Homepage
Vienna, Austria,
2010-08-03 18:38
(5397 d 15:35 ago)

Posting: # 5711
Views: 9,152
 

 EMA: Questions & Answers [BE/BA News]

Post reply
Dear all,

'Questions & Answers: Positions on specific questions addressed to the EWP therapeutic subgroup on Pharmacokinetics' were updated on 22 July 2010.

Two issues, namely
  • Bioequivalence studies for paroxetine (single dose versus multiple dose studies) and
  • Interpretation of bioequivalence data in relation to both parent and metabolite PK data
were deleted, since they are covered in the new BE-GL.

Other points were updated
  • Requirements for food-interaction studies for modified release formulations
  • Bioequivalence of gastro-resistant preparations (e.g. omeprazole)
  • Bioequivalence studies for generic products containing clopidogrel
or added, namely
  • Acceptance criteria for bioequivalence studies for losartan
  • Bioequivalence assessment of generics for tacrolimus
  • Requirements for demonstration of bioequivalence for ciclosporine generics
—
Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
 
Jaime_R
★★  

Barcelona,
2010-08-03 19:03
(5397 d 15:09 ago)

@ Helmut
Posting: # 5712
Views: 7,509
 

 Acceptance ranges

Post reply
Dear Helmut and all,

interesting; now we have the first official statement about some NTIDs!
  • Tacrolimus: 90%-111% for AUC and 80%-125% for Cmax
  • Ciclosporine: 90%-111% for AUC and Cmax (fasting and fed)
Also a clear statement, where widening for Cmax is not acceptable (Clopidogrel, Losartan).
—
Regards, Jaime
 
UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
172 visitors (0 registered, 172 guests [including 4 identified bots]).
Forum time: 10:13 CEST (Europe/Vienna)

Only dead fish go with the current.    Scuba divers' proverb

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5